"Medical Speed Reading Society" new crown rehabilitation of the blood sold at a high price, the third round of collection kick-off

Kangmei Pharmaceuticals was fined 600,000 by the CSRC and banned from the market; two new crown vaccines are expected to be completed in July; the team of Shanghai Ruijin Hospital published clinical results of hydroxychloroquine: no significant efficacy; and the listing of the medical device "star stock" Peijia Medical ..On May 14th, from 0 to 24 hours, 31 provinces (autonomous regions, municipalities directly under the central government) and Xinjiang Production and Construction Corps reported 4 new confirmed cases, all of which were local cases (both in Jilin); (The official website of the National Health and Health Commission)it is understood that the National Health Insurance Administration held a meeting on the 15th in Shanghai Pharmaceutical Centralized Tender procurement managementIt is understood that the meeting of the National Health Insurance Administration internal meeting, did not invite enterprises to participate, and the officials involved in the meeting had previously been responsible for the national transport procurement of the national health insurance bureau principal officials, and the content of the meeting is related to the national collection-related work(E drug manager)14, Gansu Province Public Resources Trading Bureau issued "on the application for the withdrawal of drugs to cancel the bid to register the network related matters notice (32nd batch) Gan trading medical word (2020) No52." According to the notice, 19 drugs from 14 enterprises recently submitted applications for withdrawal due to production line transformation, rising costs, shortage of raw materials, discontinuation of production, etc., which could not guarantee the normal supply of medical institutions in Gansu Province(Gansu Public Resources Trading Bureau)According to the New York Times, some biotech companies are selling the blood of new crown rehabilitation rsandated at high prices, even without their knowledgeCurrently, the maximum price per milliliter of blood is $50,000The biotech companies also classify the collected blood samples, which have higher antibody content and the higher the pricerecently, the CSRC, in accordance with the law, made an administrative penalty and a market ban decision on the case of illegal and illegal laws and regulations of Kangmei Pharmaceuticals, decided to order The Company to correct it, give a warning, and impose a fine of 600,000 yuan, a fine ranging from 900,000 yuan to 100,000 yuan to 21 responsible persons, and a 10-year ban on the securities market for 6 principal stakeThe relevant intermediary agencies suspected of illegal violations are in the administrative investigation processAt the same time, the CSRC has transferred Kangmei Pharmaceuticals and related personnel to the judicial authorities for suspected criminal acts(Sina Pharmaceutical News)days ago, Bollinger Ingeheim announced the acquisition of Northern LP's wholly owned subsidiary, Northern Biologics IncNorthern's focus on therapeutic antibodies targeting tumor microenvironments has put Bollinger Ingerheim at the forefront of matrix biology, an emerging field of tumor immunity (Sina Pharmaceutical News) today, involved medical device company Peijia Medical listed in Hong Kong Today's opening price was 26.8 yuan, up more than 70% Zeng Yixin, deputy director of the National Health and Committee, said that there is currently a recombinant adenovirus vector vaccine, and four inactivated vaccines have been approved by the State Drug Administration to carry out the first and second phase of combined clinical trials; The results of the 15, the results of the study showed that the use of hydroxychloroquine can not significantly improve the mild to moderate new coronaof hospitalization patients nucleic acid conversion, and side effects are higher than standard treatment The results are contrary to the positive conclusions of a previous non-randomized clinical trial of oxychloroquine Takeda Pharmaceuticals, , announced that the European Union has expanded Adcetris' marketing authority to include: Adcetris United CHP (cyclophosphamide and amycin-strong pine) for the previously untreated adult patients with systemic transsexual large cell lymphoma SALCL is a type of peripheral T-cell lymphoma (Sina Pharmaceutical News) 15, the State Drug Administration officially accepted the rare disease neurospinal cord itisis spectrum disease (NMOSD) treatment drug satralizumab market license application (State Drug Administration) Gan Li Pharmaceuticals three generations of insulin similarity winter insulin injection was approved by the State Drug Administration for the treatment of diabetes, AstraZeneca "Glong bromumammonium Fomotro inhalation aerosol agent" approved by the State Drug Administration for the treatment of chronic obstructive pulmonary disease, Shanghai Shili according to the new class 4 application "iodine paol injection" approved by the State Drug Administration, the same conformity evaluation This is the first domestic drug through the consistency evaluation of the manufacturer (Pharmaceutical Rubik's Cube) 15, Hengrui submitted a new class 4 generic drug niobium alcohol injection application to obtain CDE acceptance, the drug for the National Health and Reform Commission "the first batch of incentives to copy the drug catalog list" products, Hengrui for the first domestic to submit the drug listing application manufacturers The , Hansen Pharmaceuticals announced that the new Class 2 biological drug HS-20090 injection, developed by its subsidiary Hansen Bio and Howson Pharmaceuticals, has been approved for clinical treatment In recent years, Howson pharmaceutical research and development efforts have been strengthened year by year, innovation inflection point has come (MINET) Roche announced that its TIGIT inhibitor tiragolumab and PD-L1 inhibitor Tecentriq were combined as first-line therapies to obtain positive clinical data in the phase 2 clinical study CITYSCAPE for the treatment of PD-L1-positive metastatic non-small cell lung cancer patients (Pharmaceutical Mingkant) Pfizer announced on the 14th a 20-price pneumococcal polysaccharide vaccine (20vPnC) Phase 3 clinical study results The study assessed the consistency and safety of three different batches of 20vPnC that caused an immune response in adults aged 18 to 49 who had not been vaccinated against pneumococcal The results showed that 20vPnC in three batches had an equivalent response to all 20 serotypes, meeting the main immunogenicity objectives of the study At the same time, the security of 20vPnC was similar to that of the Prevnar13 ® control group The study is expected to meet licensing requirements for production consistency by the FDA and other national regulators (Sina Pharmaceutical News) Baishi MeiShibao announced on the 15th, CheckMate870 research reached the main end of clinical research CheckMate870 is an open labeled Phase IIIB clinical study designed to assess the safety and effectiveness of odivist use in patients with advanced non-small cell lung cancer after 1-2 systematic treatments The study included 400 Asian patients, 394 of whom were Chinese, and the main focus of the study was to assess the incidence of high-level (3-5 level) adverse reactions in patients with treated non-small cell lung cancer with advanced non-HBV infection recently, Immunomedics announced that its ADC drug Sacituzumabgovitecan (IMMUNO-132) for the treatment of three-yin breast cancer, the third phase of clinical ASCENT study due to the efficacy of outstanding early termination, will be expected to further accelerate the FDA approval and marketing (CPhI PharmaceuticalS.) Johnson and Johnson's Janssen Pharmaceuticals recently announced the latest results of the BCMACAR-T cell therapy JNJ-4528Ib/II PHASE CARTITUDE-1 study (NCT03548207) JNJ-4528 is a research B-cell-mature antigen (BCMA)-oriented chimeric antigen receptor T-cell (CAR-T) therapy (Bio Valley) Sanofi recently announced that the U.S FDA has accepted the application for a permit for the treatment of hemolytic biological products in adult patients with primary condensate-concentration disease, and granted priority review Sutimlimab is a research monoantigen that targets the internal cause of CAD hemolytic by selectively inhibiting complement C1s (Bio Valley) 14, the State Drug Administration approved the development and production of human glutagon-like peptide-1 (GLP-1) analogues of noando and ® (liraglu peptide injection) cardiovascular indications market application Specific elements of this approved indication include: the main risk of adverse cardiovascular events in adult patients with type 2 diabetes with cardiovascular disease At this point, liraglutide injection will become the only sugar-reducing drug in China with reduced cardiovascular risk indications (Sina Pharmaceutical News) Syntekabio, a drug development company based on artificial intelligence and next-generation sequencing, presented the results of the STB-C017 animal trial at the 2020 annual meeting of the American Society for Cancer Research at 00:00 EST, and STB-C017 is a small molecule IDO/TDO inhibitor derived from Stekabio's AI drug discovery platform (AP) - The latest data from the world's first PROTACs drug human trial (NCT03888612) is published in the SUMMARy of the ANNUAL MEETING of ASCO The Phase I/II clinical trial evaluated Arvinas, a candidate drug, ARV-110, in patients with metastatic prostate cancer ARV-110 is an oral protein degradation agent that targets androgen receptors based on PROTACs technology (Pharmaceutical Rubik's Cube) Genesis today announced a global strategic cooperation agreement with Affibody, an innovative autoimmune drug, and Affibody, Sweden Genesis will receive exclusive development and commercialization rights in china, Hong Kong, Taiwan, Macau and South Korea, as well as the right to clinical development in the Asia-Pacific region outside Japan The two sides also announced that they will cooperate in a number of global clinical trials to achieve the goal of simultaneous registration in multiple countries (American News Agency)